Bonsity

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 9/1/2021
Bonsity Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Bonsity?

Bonsity (teriparatide injection) is a parathyroid hormone analog (PTH 1- 34) indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture; to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture; and for treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.

What Are Side Effects of Bonsity?

Common side effects of Bonsity include:

Dosage for Bonsity

The recommended dose of Bonsity is 20 mcg subcutaneously once a day.

What Drugs, Substances, or Supplements Interact with Bonsity?

Bonsity may interact with digoxin. Tell your doctor all medications and supplements you use.

Bonsity During Pregnancy or Breastfeeding

Bonsity is not recommended for use during pregnancy; it is unknown how it would affect a fetus. It is unknown if Bonsity passes into breast milk. Because of a possible potential for osteosarcoma, breastfeeding is not recommended during treatment with Bonsity.

Additional Information

Our Bonsity (teriparatide injection) for Subcutaneous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

What is another medical term for osteoporosis? See Answer
Bonsity Professional Information

SIDE EFFECTS

Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Treatment Of Osteoporosis In Men And Postmenopausal Women

The safety of teriparatide in the treatment of osteoporosis in men and postmenopausal women was assessed in two randomized, double-blind, placebo-controlled trials of 1382 patients (21% men, 79% women) aged 28 to 86 years (mean 67 years). The median durations of the trials were 11 months for men and 19 months for women, with 691 patients exposed to teriparatide and 691 patients to placebo. All patients received 1000 mg of calcium plus at least 400 IU of vitamin D supplementation per day.

The incidence of all cause mortality was 1% in the teriparatide group and 1% in the placebo group. The incidence of serious adverse events was 16% in teriparatide patients and 19% in placebo patients. Early discontinuation due to adverse events occurred in 7% of teriparatide patients and 6% of placebo patients.

Table 1 lists adverse events from the two principal osteoporosis trials in men and postmenopausal women that occurred in ≥2% of teriparatide-treated and more frequently than placebo-treated patients.

Table 1. Percentage of Patients with Adverse Events Reported by at Least 2% of Teriparatide-Treated Patients and in More Teriparatide-Treated Patients than Placebo-Treated Patients from the Two Principal Osteoporosis Trials in Women and Men (Adverse Events are Shown Without Attribution of Causality)

  Teriparatide
N=691
Placebo
N=691
Event Classification (%) (%)
Body as a Whole
Pain 21.3 20.5
Headache 7.5 7.4
Asthenia 8.7 6.8
Neck pain 3.0 2.7
Cardiovascular
Hypertension 7.1 6.8
Angina pectoris 2.5 1.6
Syncope 2.6 1.4
Digestive System
Nausea 8.5 6.7
Constipation 5.4 4.5
Diarrhea 5.1 4.6
Dyspepsia 5.2 4.1
Vomiting 3.0 2.3
Gastrointestinal disorder 2.3 2.0
Tooth disorder 2.0 1.3
Musculoskeletal
Arthralgia 10.1 8.4
Leg cramps 2.6 1.3
Nervous System
Dizziness 8.0 5.4
Depression 4.1 2.7
Insomnia 4.3 3.6
Vertigo 3.8 2.7
Respiratory System
Rhinitis 9.6 8.8
Cough increased 6.4 5.5
Pharyngitis 5.5 4.8
Dyspnea 3.6 2.6
Pneumonia 3.9 3.3
Skin and Appendages
Rash 4.9 4.5
Sweating 2.2 1.7

Laboratory Findings

Serum Calcium

Teriparatide transiently increased serum calcium, with the maximal effect observed at approximately 4 to 6 hours post-dose. Serum calcium measured at least 16 hours post-dose was not different from pretreatment levels. In clinical trials, the frequency of at least 1 episode of transient hypercalcemia in the 4 to 6 hours after teriparatide administration was increased from 2% of women and none of the men treated with placebo to 11% of women and 6% of men treated with teriparatide. The number of patients treated with teriparatide whose transient hypercalcemia was verified on consecutive measurements was 3% of women and 1% of men.

Urinary Calcium

Teriparatide increased urinary calcium excretion, but the frequency of hypercalciuria in clinical trials was similar for patients treated with teriparatide and placebo [see CLINICAL PHARMACOLOGY].

Serum Uric Acid

Teriparatide increased serum uric acid concentrations. In clinical trials, 3% of teriparatide patients had serum uric acid concentrations above the upper limit of normal compared with 1% of placebo patients. However, the hyperuricemia did not result in an increase in gout, arthralgia, or urolithiasis.

Renal Function

No clinically important adverse renal effects were observed in clinical studies. Assessments included creatinine clearance; measurements of blood urea nitrogen (BUN), creatinine, and electrolytes in serum; urine specific gravity and pH; and examination of urine sediment.

Studies In Men And Women With Glucocorticoid-Induced Osteoporosis

The safety of teriparatide in the treatment of men and women with glucocorticoid-induced osteoporosis was assessed in a randomized, double-blind, active-controlled trial of 428 patients (19% men, 81% women) aged 22 to 89 years (mean 57 years) treated with ≥5 mg per day prednisone or equivalent for a minimum of 3 months. The duration of the trial was 18 months with 214 patients exposed to teriparatide and 214 patients exposed to oral daily bisphosphonate (active control). All patients received 1000 mg of calcium plus 800 IU of vitamin D supplementation per day.

The incidence of all cause mortality was 4% in the teriparatide group and 6% in the active control group. The incidence of serious adverse events was 21% in teriparatide patients and 18% in active control patients, and included pneumonia (3% teriparatide, 1% active control). Early discontinuation because of adverse events occurred in 15% of teriparatide patients and 12% of active control patients, and included dizziness (2% teriparatide, 0% active control).

Adverse events reported at a higher incidence in the teriparatide group and with at least a 2% difference in teriparatide-treated patients compared with active control-treated patients were: nausea (14%, 7%), gastritis (7%, 3%), pneumonia (6%, 3%), dyspnea (6%, 3%), insomnia (5%, 1%), anxiety (4%, 1%), and herpes zoster (3%, 1%), respectively.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of teriparatide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Osteosarcoma: Cases of bone tumor and osteosarcoma have been reported rarely in the postmarketing period. The causality to teriparatide use is unclear. Long term osteosarcoma surveillance studies are ongoing [see WARNINGS AND PRECAUTIONS].
  • Hypercalcemia: Hypercalcemia greater than 13.0 mg/dL has been reported with teriparatide use.

Adverse events reported since market introduction that were temporally (but not necessarily causally) related to teriparatide therapy include the following:

  • Allergic Reactions: Anaphylactic reactions, drug hypersensitivity, angioedema, urticaria
  • Investigations: Hyperuricemia
  • Respiratory System: Acute dyspnea, chest pain
  • Musculoskeletal: Muscle spasms of the leg or back
  • Other: Injection site reactions including injection site pain, swelling and bruising; oro-facial edema

Immunogenicity

As with all peptides, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to teriparatide in the study described below with the incidence of antibodies in other studies or to other teriparatide products may be misleading.

The immunogenicity profile of BONSITY was evaluated in a 24-week randomized trial comparing the effects of BONSITY 20 mcg daily with another teriparatide product 20 mcg daily. In this trial, 2.2% (2/90) subjects who received BONSITY and 2.2% (2/91) subjects who received the other teriparatide product had detectable antibodies to teriparatide and one out of the two BONSITY treated patients developed neutralizing antibodies to teriparatide.

Read the entire FDA prescribing information for Bonsity (Teriparatide Injection, for Subcutaneous Use)

SLIDESHOW

Osteoporosis Super-Foods for Strong Bones With Pictures See Slideshow

© Bonsity Patient Information is supplied by Cerner Multum, Inc. and Bonsity Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors